Literature DB >> 12359653

Synthetic serine elastase inhibitor reduces cigarette smoke-induced emphysema in guinea pigs.

Joanne L Wright1, Stephen G Farmer, Andrew Churg.   

Abstract

To test whether a serine elastase inhibitor could prevent or reduce emphysema, we exposed guinea pigs to cigarette smoke acutely, or daily for 6 months, and treated some animals with the neutrophil elastase inhibitor ZD0892. Acute smoke exposure increased lavage neutrophils and increased desmosine and hydroxyproline, measures of elastin and collagen breakdown; all these measures were reduced by ZD0892. Long-term smoke exposure produced emphysema and increases in lavage neutrophils, desmosine, hydroxyproline, and plasma tumor necrosis factor alpha (TNF-alpha). ZD0892 treatment returned lavage neutrophils, desmosine, and hydroxyproline levels to control values, and decreased airspace enlargement by 45% and TNF-alpha by 30%. Animals exposed to smoke for 4 months and then to smoke plus ZD0892 for 2 months were not protected against emphysema. Mice exposed to smoke showed increases in gene expression of neutrophil chemoattractant macrophage inflammatory protein-2, macrophage chemoattractant protein-1, and TNF-alpha at 2 hours along with increased plasma TNF-alpha; ZD0892 prevented the increases in macrophage inflammatory protein-2 and macrophage chemoattractant protein-1 expression and reduced plasma TNF-alpha levels to baseline. These data demonstrate that a serine elastase inhibitor ameliorates the inflammatory and destructive effects of cigarette smoke, and that these effects are mediated in part by neutrophils and by smoke-driven TNF-alpha production.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12359653     DOI: 10.1164/rccm.200202-098OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  22 in total

Review 1.  Acute effects of cigarette smoke on inflammation and oxidative stress: a review.

Authors:  H van der Vaart; D S Postma; W Timens; N H T ten Hacken
Journal:  Thorax       Date:  2004-08       Impact factor: 9.139

Review 2.  Proteinases and oxidants as targets in the treatment of chronic obstructive pulmonary disease.

Authors:  Caroline A Owen
Journal:  Proc Am Thorac Soc       Date:  2005

3.  Imbalance of apoptosis and cell proliferation contributes to the development and persistence of emphysema.

Authors:  Ji-Hyun Lee; Masayuki Hanaoka; Yoshiaki Kitaguchi; Donatas Kraskauskas; Leland Shapiro; Norbert F Voelkel; Laima Taraseviciene-Stewart
Journal:  Lung       Date:  2011-10-21       Impact factor: 2.584

4.  A Pulmonary Perspective on GASPIDs: Granule-Associated Serine Peptidases of Immune Defense.

Authors:  George H Caughey
Journal:  Curr Respir Med Rev       Date:  2006-08

5.  Activated charcoal filter effectively reduces p-benzosemiquinone from the mainstream cigarette smoke and prevents emphysema.

Authors:  Neekkan Dey; Archita Das; Arunava Ghosh; Indu B Chatterjee
Journal:  J Biosci       Date:  2010-06       Impact factor: 1.826

Review 6.  Barriers to inhaled gene therapy of obstructive lung diseases: A review.

Authors:  Namho Kim; Gregg A Duncan; Justin Hanes; Jung Soo Suk
Journal:  J Control Release       Date:  2016-05-16       Impact factor: 9.776

7.  Antiproteases as therapeutics to target inflammation in cystic fibrosis.

Authors:  Derek J Quinn; Sinéad Weldon; Clifford C Taggart
Journal:  Open Respir Med J       Date:  2010-03-30

8.  Targeting lung inflammation: novel therapies for the treatment of COPD.

Authors:  Hongwei Yao; Willem I de Boer; Irfan Rahman
Journal:  Curr Respir Med Rev       Date:  2008

Review 9.  Roles for proteinases in the pathogenesis of chronic obstructive pulmonary disease.

Authors:  Caroline A Owen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

Review 10.  Targeted treatment in COPD: a multi-system approach for a multi-system disease.

Authors:  David Anderson; William Macnee
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.